Baader Helvea downgraded Newron Pharma to Add from Buy with a price target of CHF 7.20, up from CHF 2.60. The analyst updated the model to account for evenamide’s recent success in the open-label trial in treatment-resistant schizophrenia. It cites valuation for the downgrade.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly